Gastroenterology
Volume 136, Issue 2 , Pages 496-504.e3 , February 2009

Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses

Interim results of this trial were presented at the 49th International Association for the Study of the Liver meeting, September 7–11, 2006, Cairo, Egypt; at the 42nd European Association for the Study of the Liver meeting, April 11–15, 2007, Barcelona, Spain; at the 58th American Association for the Study of the Liver Meeting, November 1–5, 2007, Boston, MA; at the 17th Asian Pacific Association for the Study of the Liver meeting, March 25–28, 2007, Kyoto, Japan; at the 18th Asian Pacific Association for the Study of the Liver meeting, March 23–26, 2008, Seoul, South Korea; and at the 43rd European Association for the Study of the Liver meeting, April 23–27, 2008, Milan, Italy.

  • Chun–Jen Liu

      Affiliations

    • National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Wan–Long Chuang

      Affiliations

    • Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
    • ,
  • Chuan–Mo Lee

      Affiliations

    • Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, Taiwan
    • ,
  • Ming–Lung Yu

      Affiliations

    • Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
    • ,
  • Sheng–Nan Lu

      Affiliations

    • Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, Taiwan
    • ,
  • Shun–Sheng Wu

      Affiliations

    • Changhua Christian Hospital, Changhua, Taiwan
    • ,
  • Li–Ying Liao

      Affiliations

    • Taipei City Hospital, Ren-Ai Branch, Taipei, Taiwan
    • ,
  • Chi–Ling Chen

      Affiliations

    • National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Hsing–Tao Kuo

      Affiliations

    • Chi Mei Medical Center, Tainan, Taiwan
    • ,
  • You–Chen Chao

      Affiliations

    • Tri-Service General Hospital, Taipei, Taiwan
    • ,
  • Shui–Yi Tung

      Affiliations

    • Chia-Yi Chang Gung Memorial Hospital, Chiayi Hsien, Taiwan
    • ,
  • Sien–Sing Yang

      Affiliations

    • Cathay General Hospital, Taipei, Taiwan
    • ,
  • Jia–Horng Kao

      Affiliations

    • National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Chen–Hua Liu

      Affiliations

    • National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Wei–Wen Su

      Affiliations

    • Changhua Christian Hospital, Changhua, Taiwan
    • ,
  • Chih–Lin Lin

      Affiliations

    • Taipei City Hospital, Ren-Ai Branch, Taipei, Taiwan
    • ,
  • Yung–Ming Jeng

      Affiliations

    • National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Pei–Jer Chen

      Affiliations

    • National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Ding–Shinn Chen

      Affiliations

    • National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
    • Corresponding Author InformationAddress requests for reprints to: Ding–Shinn Chen, MD, Distinguished Chair Professor, Department of Internal Medicine, National Taiwan University College of Medicine, 1 Chang-Te Street, Taipei 10002, Taiwan. fax: (886) 2-23317624

Received 16 July 2008 ,Accepted 23 October 2008.

References 

  1. Chen DS, Kuo G, Sung JL, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis. 1990;162:817–822
  2. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology. 1995;22:1101–1108
  3. Liu CJ, Liou JM, Chen DS, et al. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc. 2005;104:783–791
  4. Sagnelli E, Coppola N, Messina V, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology. 2002;36:1285–1291
  5. Sagnelli E, Pasquale G, Coppola N, et al. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection. 2004;32:144–148
  6. Sun CA, Wu DM, Lin CC, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol. 2003;157:674–682
  7. Liaw YF, Chien RN, Lin SM, et al. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res. 1997;17:449–452
  8. Villa E, Grottola A, Buttafoco P, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol. 2001;96:2973–2977
  9. Zignego A, Fontana R, Puliti S, et al. Impaired response to alpha interferon in patients with an apparent hepatitis B and hepatitis C virus coinfections. Arch Virol. 1997;142:535–544
  10. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 1996;111:1307–1312
  11. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426–1432
  12. Reichard O, Norkrans G, Fryden A, et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C (The Swedish Study Group). Lancet. 1998;351:83–87
  13. Liu CJ, Chen PJ, Lai MY, et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003;37:568–576
  14. Chuang WL, Dai CY, Chang WY, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther. 2005;10:125–133
  15. Hung CH, Lee CM, Lu SN, et al. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol. 2005;20:727–732
  16. Urganci N, Gulec S, Dogan S, et al. Interferon and ribavirin treatment results of patients with HBV-HCV co-infection cured of childhood malignancies. Int J Infect Dis. 2006;10:453–457
  17. Liu CJ, Chen PJ, Chen DS. A forgotten population with chronic hepatitis C infection: subjects coinfected with hepatitis B virus. Hepatology. 2004;40:266
  18. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666–1672
  19. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673–1680
  20. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395–403
  21. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965
  22. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  23. Lee SD, Yu ML, Cheng PN, et al. Comparison of a 6-month course peginterferon α-2b plus ribavirin and interferon α-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat. 2005;12:283–291
  24. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22–26
  25. Mrani S, Chemin I, Menouar K, et al. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol. 2007;79:1075–1081
  26. Sagnelli E, Coppola N, Scolastico C, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology. 2000;32:1106–1110
  27. Saitta C, Pontisso P, Brunetto MR, et al. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy. Antiviral Ther. 2006;11:931–934
  28. Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol. 2004;41:659–666
  29. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47:598–607
  30. Browner WS, Black D, Newman TB, et al. Estimating sample size and power. In:  Hulley SB,  Cummings SR editor. Designing clinical research: an epidemiologic approach. Baltimore, MD: Williams & Wilkins; 1988;p. 139–150
  31. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–2695
  32. Yu ML, Dai CY, Huang JF, et al. A randomized study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007;56:553–559
  33. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008;47:1884–1893
  34. Hsu CS, Liu CJ, Lai MY, et al. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology. 2007;50:310–315
  35. Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007;297:724–732
  36. McCaughan GW, Omata M, et al. Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007;22:615–633
  37. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45:1187–1192
  38. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133:1437–1444
  39. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206–1217
  40. Yalcin K, Degertekin H, Yildiz F, et al. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J Gastroenterol. 2003;38:796–800

 The statistical analysis of the entire data sets pertaining to efficacy and safety was performed independently by a biostatistician (C.–L. Chen, National Taiwan University College of Medicine) who is not employed by the corporate entity.

 The corresponding authors (D.–S. Chen and P.–J. Chen) had full access to all of the data and take full responsibility for the veracity of the data and analysis. The study sponsors did not play any role in the study design; in the collection, analysis, and interpretation of data; and in the decision to submit the report for publication.

 US National Institutes of Health registration number for clinical trial: NCT00361179. An Open Label, Comparative, Multi-Center Study, To Evaluate the Efficacy and Safety of Peginterferon Alfa-2a Plus Ribavirin in the Treatment of Patients With Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C.

 The authors disclose the following: This study was supported in part by grants from the Department of Health, the National Science Council, Executive Yuan, Taiwan; National Taiwan University; and National Health Research Institutes, Taiwan.

PII: S0016-5085(08)01887-8

doi: 10.1053/j.gastro.2008.10.049

Gastroenterology
Volume 136, Issue 2 , Pages 496-504.e3 , February 2009

Article Tools

* Image Usage & Resolution